Skip to content
Baltimore News Journal – Lifestyle
Author:
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes
June 8, 2026
Sparrow Pharmaceuticals Announces Acceptance of Late-Breaking Presentation of Interim Part 1 Results from CAPTAIN-T2D at the Endocrine Society (ENDO) 2026 Annual Meeting
June 3, 2026
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
May 29, 2026